CRASH-3
Tranexamic Acid in Traumatic Brain Injury
Patient / Population Intervention / Exposure Comparison Outcome
In 12,737 patients with traumatic brain injury, tranexamic acid did not reduce head-injury death overall versus placebo, with benefit in mild–moderate TBI.
N
12,737
Design
International RCT
Endpoint
Head-injury-related death within 28 days
Relevance
3
Result18.5% vs 19.8% (RR 0.94; 95% CI 0.86–1.02). Mild–moderate TBI subgroup benefit.
CRASH-3 Trial Collaborators. Lancet. 2019;394(10210):1713-1723. 10.1016/S0140-6736(19)32233-0
Discussion & critique
Modest overall, but supports early TXA for mild–moderate TBI given the low cost and safety.